search
Back to results

Improving the Efficacy of Anti-Nicotine Immunotherapy (PETNic002)

Primary Purpose

Nicotine Dependence

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
NIC002 in Aluminum hydroxide (Alum)
Placebo Vaccine - Aluminum hydroxide
Sponsored by
Alexey Mukhin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Nicotine Dependence

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18-55 years old
  • Smoked an average of at least 10 cigarettes per day for the past year
  • Have an expired air Carbon Monoxide (CO) reading of at least 15 ppm
  • Express a desire to quit smoking in the next three to four months.
  • Potential subjects must agree to use acceptable contraception during their participation in this study.
  • Potential subjects must agree to avoid the following during their participation in this study:
  • participation in any other nicotine-related modification strategy outside of this protocol
  • use of tobacco products other than cigarettes, including pipe tobacco, cigars, snuff, and chewing tobacco

    • use of experimental (investigational) drugs or devices;
    • use of illegal drugs;
    • use of psychiatric medications;
    • use of opiate medications;
    • use of systemic steroids or other immunosuppressive agents.

Exclusion Criteria:

  1. Hypertension (systolic >140 mm Hg, diastolic >100 mm Hg, coupled with a history of hypertension); subjects with no previous diagnosis of hypertension may have a screening blood pressure up to 160/100.
  2. Hypotension with symptoms (systolic <90 mm Hg, diastolic <60 mm Hg).
  3. Participants with a history of hypertension may, however, be allowed to participate in the study if the study physician or physician assistant determines that the condition is stable, controlled by medication, and in no way jeopardizes the individual's safety.
  4. Coronary heart disease or other cardiovascular disorder;
  5. Lifetime history of heart attack;
  6. Cardiac rhythm disorder (irregular heart rhythm);
  7. Chest pains (unless history, exam, and Electrocardiogram (ECG) clearly indicate a non-cardiac source);
  8. Cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);
  9. Liver or kidney disorder (except kidney stones, gallstones);
  10. Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;
  11. Active ulcers in the past 30 days;
  12. Lung disorder (including but not limited to chronic obstructive pulmonary disease (COPD), emphysema, and asthma);
  13. Brain abnormality or other neurological disorder (including but not limited to stroke, brain tumor, and seizure disorder);
  14. Recent, unexplained fainting spells;
  15. Problems giving blood samples;
  16. Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less than 180mg/dcl and HbA1c is less than 7%);
  17. Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer);
  18. Skin disorder;
  19. Autoimmune disease;
  20. Human immunodeficiency virus (HIV) or HIV risk behavior;
  21. Severe allergies;
  22. Other major medical condition;
  23. Current psychiatric disease including major depressive episode, panic attack, psychosis, bipolar disorder or eating disorder;
  24. Pregnant or nursing mothers;
  25. Use (within the past 30 days) of:

    • Illegal drugs (or if the urine drug screen is positive),
    • Experimental (investigational) drugs;
    • Psychiatric medications including antidepressants, anti-psychotics or any other medications that are known to affect smoking cessation (e.g. clonidine);
    • Opiate medications for pain or sleep (non-opiate medication for pain or sleep will be allowed)
    • Smokeless tobacco (chewing tobacco, snuff), cigars, pipes or e-cigarettes;
    • Nicotine replacement therapy or any other smoking cessation aid.
  26. Alcohol abuse - The AUDIT (Alcohol Use Disorders Identification Test) questionnaire will be used to assess alcohol abuse.
  27. Previous history of negative experiences with "flu" vaccine or any other vaccine.
  28. High chronic exposure to aluminum (occupational or medical);
  29. Pulmonary function test results < 60% of predicted value for FEV1 and FVC;
  30. Body Mass Index > 38kg/m2;
  31. History of psychosis or bipolar disorder;
  32. Prior exposure to CTY002- NicQ or any other nicotine vaccine.

Sites / Locations

  • Duke Center for Nicotine & Smoking Cessation Research
  • Wake Forest University Health Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

NIC002 Vaccine in Aluminum hydroxide

Placebo Vaccine - Aluminum hydroxide

Arm Description

4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.

4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.

Outcomes

Primary Outcome Measures

Vaccine-Induced Percent Change in Brain Nicotine Area Under Curve (AUC) After Single or Multiple (7) Puffs
There was a 2 hour washout period between the "single puff" and "multiple puffs" assessments.
Vaccine-Induced Percent Change in Brain Nicotine Maximum Concentration After Single or Multiple (7) Puffs
There was a 2 hour washout period between the "single puff" and "multiple puffs" assessments.
Vaccination-Induced Percent Change in T1/2 of Brain Nicotine Accumulation After Single or Multiple (7) Puffs
There was a 2 hour washout period between the "single puff" and "multiple puffs" assessments.
Vaccination-Induced Percent Change in Initial Slope of Brain Nicotine Accumulation After a Single Puff

Secondary Outcome Measures

Full Information

First Posted
November 16, 2010
Last Updated
January 29, 2014
Sponsor
Alexey Mukhin
Collaborators
Wake Forest University Health Sciences, Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01280968
Brief Title
Improving the Efficacy of Anti-Nicotine Immunotherapy
Acronym
PETNic002
Official Title
Improving the Efficacy of Anti-Nicotine Immunotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Alexey Mukhin
Collaborators
Wake Forest University Health Sciences, Novartis Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to find out how vaccine-induced antibodies change the way the body processes nicotine from cigarettes. These antibodies absorb nicotine and can reduce nicotine levels in the brain. In this way, the vaccination may help to quit smoking. The central hypothesis is that anti-nicotine antibodies change kinetics of brain nicotine accumulation and distribution of nicotine between the brain and other body tissues. This vaccine is investigational which means that it is still being tested in research studies and is not approved by the U.S. Food and Drug Administration (FDA) to help people quit smoking.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nicotine Dependence

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
52 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NIC002 Vaccine in Aluminum hydroxide
Arm Type
Experimental
Arm Description
4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.
Arm Title
Placebo Vaccine - Aluminum hydroxide
Arm Type
Placebo Comparator
Arm Description
4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.
Intervention Type
Biological
Intervention Name(s)
NIC002 in Aluminum hydroxide (Alum)
Other Intervention Name(s)
CYT002-NicQb (Nicotine-Qbeta), Anti-Nicotine Vaccine
Intervention Description
Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
Intervention Type
Biological
Intervention Name(s)
Placebo Vaccine - Aluminum hydroxide
Intervention Description
Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
Primary Outcome Measure Information:
Title
Vaccine-Induced Percent Change in Brain Nicotine Area Under Curve (AUC) After Single or Multiple (7) Puffs
Description
There was a 2 hour washout period between the "single puff" and "multiple puffs" assessments.
Time Frame
measured at week 1 and week 16
Title
Vaccine-Induced Percent Change in Brain Nicotine Maximum Concentration After Single or Multiple (7) Puffs
Description
There was a 2 hour washout period between the "single puff" and "multiple puffs" assessments.
Time Frame
measured at week 1 and week 16
Title
Vaccination-Induced Percent Change in T1/2 of Brain Nicotine Accumulation After Single or Multiple (7) Puffs
Description
There was a 2 hour washout period between the "single puff" and "multiple puffs" assessments.
Time Frame
measured at week 1 and week 16
Title
Vaccination-Induced Percent Change in Initial Slope of Brain Nicotine Accumulation After a Single Puff
Time Frame
measured at week 1 and week 16

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-55 years old Smoked an average of at least 10 cigarettes per day for the past year Have an expired air Carbon Monoxide (CO) reading of at least 15 ppm Express a desire to quit smoking in the next three to four months. Potential subjects must agree to use acceptable contraception during their participation in this study. Potential subjects must agree to avoid the following during their participation in this study: participation in any other nicotine-related modification strategy outside of this protocol use of tobacco products other than cigarettes, including pipe tobacco, cigars, snuff, and chewing tobacco use of experimental (investigational) drugs or devices; use of illegal drugs; use of psychiatric medications; use of opiate medications; use of systemic steroids or other immunosuppressive agents. Exclusion Criteria: Hypertension (systolic >140 mm Hg, diastolic >100 mm Hg, coupled with a history of hypertension); subjects with no previous diagnosis of hypertension may have a screening blood pressure up to 160/100. Hypotension with symptoms (systolic <90 mm Hg, diastolic <60 mm Hg). Participants with a history of hypertension may, however, be allowed to participate in the study if the study physician or physician assistant determines that the condition is stable, controlled by medication, and in no way jeopardizes the individual's safety. Coronary heart disease or other cardiovascular disorder; Lifetime history of heart attack; Cardiac rhythm disorder (irregular heart rhythm); Chest pains (unless history, exam, and Electrocardiogram (ECG) clearly indicate a non-cardiac source); Cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure); Liver or kidney disorder (except kidney stones, gallstones); Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn; Active ulcers in the past 30 days; Lung disorder (including but not limited to chronic obstructive pulmonary disease (COPD), emphysema, and asthma); Brain abnormality or other neurological disorder (including but not limited to stroke, brain tumor, and seizure disorder); Recent, unexplained fainting spells; Problems giving blood samples; Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less than 180mg/dcl and HbA1c is less than 7%); Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer); Skin disorder; Autoimmune disease; Human immunodeficiency virus (HIV) or HIV risk behavior; Severe allergies; Other major medical condition; Current psychiatric disease including major depressive episode, panic attack, psychosis, bipolar disorder or eating disorder; Pregnant or nursing mothers; Use (within the past 30 days) of: Illegal drugs (or if the urine drug screen is positive), Experimental (investigational) drugs; Psychiatric medications including antidepressants, anti-psychotics or any other medications that are known to affect smoking cessation (e.g. clonidine); Opiate medications for pain or sleep (non-opiate medication for pain or sleep will be allowed) Smokeless tobacco (chewing tobacco, snuff), cigars, pipes or e-cigarettes; Nicotine replacement therapy or any other smoking cessation aid. Alcohol abuse - The AUDIT (Alcohol Use Disorders Identification Test) questionnaire will be used to assess alcohol abuse. Previous history of negative experiences with "flu" vaccine or any other vaccine. High chronic exposure to aluminum (occupational or medical); Pulmonary function test results < 60% of predicted value for FEV1 and FVC; Body Mass Index > 38kg/m2; History of psychosis or bipolar disorder; Prior exposure to CTY002- NicQ or any other nicotine vaccine.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexey G Mukhin, M.D., Ph.D.
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke Center for Nicotine & Smoking Cessation Research
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Facility Name
Wake Forest University Health Sciences
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Improving the Efficacy of Anti-Nicotine Immunotherapy

We'll reach out to this number within 24 hrs